Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
159 participants
INTERVENTIONAL
2023-06-12
2024-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of A-101 Solution in Subjects With Common Warts.
NCT02669862
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
NCT02015260
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
NCT03477448
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
NCT03977753
A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts
NCT05862441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose group
Topical administration of low dose of KPN2002
KNP2002
Dairy topical administration for 12 weeks
Middle dose group
Topical administration of middle dose of KPN2002
KNP2002
Dairy topical administration for 12 weeks
High dose group
Topical administration of high dose of KPN2002
KNP2002
Dairy topical administration for 12 weeks
Placebo group
Topical administration of placebo
Placebo of KNP2002
Dairy topical administration for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KNP2002
Dairy topical administration for 12 weeks
Placebo of KNP2002
Dairy topical administration for 12 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with common warts on the upper or lower limb
* Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration
* Subjects who have given their voluntary written consent to participate in this clinical trial
Exclusion Criteria
* Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts
* Subjects with a history of allergy to topical skin preparations
* Subjects with a history of malignant tumor within 5 years before administration of study drug
* Subjects with any of the following diseases: Malignant tumor; Serious heart disease; Poorly controlled diabetes/hypertension
* Women who are pregnant, may become pregnant, or are breastfeeding
15 Years
49 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KinoPharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kawaharamachi Dermatology
Maebashi, Gunma, Japan
Tetsuya Dermatology
Himeji, Hyōgo, Japan
Takashima Dermatology
Kobe, Hyōgo, Japan
Nishino Dermatology Clinic
Kobe, Hyōgo, Japan
Queen's Square, Dermatology, Allergy
Yokohama, Kanagawa, Japan
Asai Dermatology Clinic
Yokohama, Kanagawa, Japan
Okawa Dermatology Clinic
Sakai, Osaka, Japan
Sugai Dermatology Parkside Clinic
Utsunomiya, Tochigi, Japan
Tsunoda Clinic
Arakawa-Ku, Tokyo, Japan
Sugisawa Dermatology Clinic
Katsushika-ku, Tokyo, Japan
Igarashi Clinic
Kita-ku, Tokyo, Japan
Maruyama Dermatology Clinic
Koto-Ku, Tokyo, Japan
Todoroki Dermatology Clinic
Nakano-Ku, Tokyo, Japan
Okuda Dermatology Clinic
Setagaya-Ku, Tokyo, Japan
Hayami Dermatology
Osaka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OM202JA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.